

## NAME OF THE MEDICINE

Panvax<sup>®</sup> H1N1 Vaccine / Panvax<sup>®</sup> H1N1 Vaccine Junior  
H1N1 Pandemic influenza vaccine (split virion, inactivated).

## DESCRIPTION

Panvax<sup>®</sup> H1N1 Vaccine / Panvax<sup>®</sup> H1N1 Vaccine Junior is a purified, inactivated, monovalent, split virion (split virus) vaccine containing antigen of the following type:

A/California/7/2009 (H1N1) (A/California/7/2009 (H1N1)v-like)  
7.5 µg haemagglutinin (HA) per 0.25 mL dose  
15 µg HA per 0.5 mL dose

Each 0.5 mL dose contains, nominally: sodium chloride 4.1 mg, sodium phosphate – dibasic anhydrous 0.3 mg, sodium phosphate – monobasic 0.08 mg, potassium chloride 0.02 mg, potassium phosphate – monobasic 0.02 mg, calcium chloride 1.5 µg and thiomersal 50 µg (for multi-dose vial presentation only). Each 0.25 mL dose contains half of these quantities.

The following are also present in each 0.5 mL dose: sodium taurodeoxycholate ≤ 5 µg, ovalbumin ≤ 1.0 µg, sucrose < 10 µg, neomycin ≤ 0.7 ng, polymyxin B sulfate ≤ 0.11 ng and beta-propiolactone ≤ 1.4 ng.

The virus strain in this vaccine complies with the Australian Influenza Vaccine Committee (AIVC) decision, endorsing the World Health Organisation recommended virus for the influenza A(H1N1) vaccine.

Panvax<sup>®</sup> H1N1 Vaccine / Panvax<sup>®</sup> H1N1 Vaccine Junior is prepared from influenza virus propagated in the allantoic fluid of embryonated chicken eggs. The virus is harvested from the eggs, purified by zonal centrifugation, inactivated with beta-propiolactone and disrupted with sodium taurodeoxycholate to produce split virion particles.

Note: The vaccine is referred to as Panvax<sup>®</sup> H1N1 Vaccine throughout this document, unless the information presented is specific to the Panvax<sup>®</sup> H1N1 Vaccine Junior presentation.

## PHARMACOLOGY

Immunisation with inactivated influenza vaccines has been shown to induce antibodies to the viral surface glycoproteins, haemagglutinin and neuraminidase. These antibodies are important in the prevention of natural infection.

## CLINICAL TRIALS

Clinical trials are being conducted to assess the immunogenicity and safety of the vaccine in healthy children and adults. Additionally, these trials will inform the dose and vaccination schedule for the vaccine. These studies are ongoing; however preliminary data in adults and children show that a single dose of vaccine is sufficient to elicit a protective antibody response.

### Adults

A total of 240 participants, aged  $\geq 18$  to  $< 65$  years, were randomised to receive either a 15  $\mu\text{g}$  or 30  $\mu\text{g}$  HA dose. The serum antibody response after the first vaccine dose was assessed by the haemagglutination inhibition (HI) and viral microneutralisation (MN) assays. Similar immunogenicity results were observed for both antigen doses showing that the vaccine elicits a satisfactory immune response in a large proportion of participants. Results are provided for the 15  $\mu\text{g}$  HA antigen dose, with  $> 96\%$  of participants by HI (Table 1a) and  $> 89\%$  of participants by MN (Table 1b) achieving seroprotective antibody titres of  $\geq 40$ .

**Table 1a: Immunogenicity Results for Adult Population (HI assay)**

Serum HI antibody	15 $\mu\text{g}$ HA dose n=120 (95% CI)
Fold increase in GMT <sup>a</sup>	10.6 (7.9, 14.2)
Seroconversion or significant increase <sup>b</sup>	70.8% (61.8, 78.8)
Proportion with HI $\geq 40$	96.7% (91.7, 99.1)

<sup>a</sup> Fold increase in GMT (geometric mean titre) is the fold increase in antibody titre over the pre-vaccination GMT. <sup>b</sup> 'Seroconversion' is defined as the number of participants with a pre-vaccination titre of  $< 1:10$  achieving a post-vaccination titre value of at least 40 and 'significant increase' is defined as the number of participants with a pre-vaccination titre of  $\geq 1:10$  achieving at least a four fold increase over the pre-vaccination titre.

**Table 1b: Immunogenicity Results for Adult Population (MN assay)**

Serum HI antibody	15 $\mu\text{g}$ HA dose n=120 (95% CI)
Fold increase in GMT <sup>a</sup>	24.3 (17.2, 34.3)
Seroconversion or significant increase <sup>b</sup>	74.2% (65.4, 81.7)
Proportion with MN $\geq 40$	89.2% (82.2, 94.1)

<sup>a</sup> Fold increase in GMT (geometric mean titre) is the fold increase in antibody titre over the pre-vaccination GMT. <sup>b</sup> 'Seroconversion' is defined as the number of participants with a pre-vaccination titre of  $< 1:10$  achieving a post-vaccination titre of at least 40 and 'significant increase' is defined as the number of participants with a pre-vaccination titre of  $\geq 1:10$  achieving at least a four fold increase over the pre-vaccination titre.

### Children

In a placebo-controlled clinical trial conducted in children, aged  $\geq 6$  months to  $< 9$  years, a total of 473 participants were randomised to receive two doses of either a 7.5  $\mu\text{g}$  or 15  $\mu\text{g}$  HA antigen dose of vaccine, or placebo. Participants were further stratified into two age groups: Group A,  $\geq 6$  months to  $< 3$  years, and Group B,  $\geq 3$  years to  $< 9$  years.

After the first vaccine dose, immunogenicity results (by HI) were comparable across the age groups and antigen doses, showing that a single vaccine dose elicits a satisfactory immune response in a large proportion of participants. Results are provided for the 7.5  $\mu\text{g}$  HA antigen dose for Group A and for the 15  $\mu\text{g}$  HA antigen dose for Group B, as these are the dosages to be administered. More than 88% of

Group A participants and > 91% of Group B participants achieved seroprotective antibody titres of  $\geq 40$  (Table 2).

**Table 2: Immunogenicity Results for Paediatric Population (HI assay) After a Single Vaccine Dose**

Serum HI antibody	Group A $\geq 6$ mths to < 3 yrs (95% CI)		Group B $\geq 3$ yrs to < 9 yrs (95% CI)	
	Placebo n = 25	7.5 $\mu$ g HA dose n = 102	Placebo n = 27	15 $\mu$ g HA dose n = 102
Fold increase in GMT <sup>a</sup>	1.3 (0.9, 1.7)	13.6 (11.5, 16.0)	1.1 (0.9, 1.5)	17.2 (13.9, 21.4)
Seroconversion or significant increase <sup>b</sup>	8.0% (1.0, 26.0)	87.3% (79.2, 93.0)	3.7% (0.1, 19.0)	89.2% (81.5, 94.5)
Proportion with HI $\geq 40$	12.0% (2.5, 31.2)	88.2% (80.4, 93.8)	22.2% (8.6, 42.3)	91.2% (83.9, 95.9)

<sup>a</sup> Fold increase in GMT (geometric mean titre) is the fold increase in antibody titre over the pre-vaccination GMT. <sup>b</sup> 'Seroconversion' is defined as the number of participants with a pre-vaccination titre of < 1:10 achieving a post-vaccination titre value of at least 40 and 'significant increase' is defined as the number of participants with a pre-vaccination titre of  $\geq 1:10$  achieving at least a four fold increase over the pre-vaccination titre.

## INDICATIONS

For active immunisation to prevent influenza disease caused by the influenza A(H1N1) virus in persons from 6 months of age.

## CONTRAINDICATIONS

Anaphylactic hypersensitivity to previous influenza vaccination, or to eggs, thiomersal (for thiomersal-containing vaccine only), neomycin, polymyxin B sulfate or any of the constituents or trace residues (see Description section) of this vaccine.

Immunisation must be postponed in people who have febrile illness or acute infection.

## PRECAUTIONS

As with all injectable vaccines, appropriate medical treatment and supervision should always be available to manage the rare event of an anaphylactic reaction following administration of the vaccine.

Minor illness, with or without fever, should not contraindicate the use of influenza vaccine.

In immunocompromised patients, the antibody response may be lower.

If Guillain-Barré syndrome has occurred within six weeks of previous influenza vaccination, the decision to give Panvax® H1N1 Vaccine should be based on careful consideration of the potential benefits and risks.

---

**Use in pregnancy: (Category B2)**

The safety profile of Panvax<sup>®</sup> H1N1 Vaccine in pregnant women is unknown. An animal reproduction study conducted with CSL's seasonal influenza vaccine, Fluvax<sup>®</sup> vaccine, did not demonstrate any maternal or developmental toxicity. Healthcare professionals should assess the potential benefits and risks of administering Panvax<sup>®</sup> H1N1 Vaccine to pregnant women on a case by case basis, taking into account Australian Health Authorities' recommendations.

**Use in lactation:**

The safety profile of the vaccine in lactating women is unknown. Healthcare professionals should assess the potential benefits and risks of administering Panvax<sup>®</sup> H1N1 Vaccine to lactating women on a case by case basis, taking into account Australian Health Authorities' recommendations.

**Paediatric use:**

There are no clinical data for children under 6 months of age.

**Interactions with other medicines:**

The immunological response may be diminished if the patient is undergoing corticosteroid or immunosuppressant treatment.

There are no data to assess the concomitant administration of Panvax<sup>®</sup> H1N1 Vaccine with other vaccines. If Panvax<sup>®</sup> H1N1 Vaccine is to be given at the same time as another injectable vaccine, the vaccines should be administered at different injection sites.

## **ADVERSE EFFECTS**

**Clinical Trial (Adults):**

Clinical data show Panvax<sup>®</sup> H1N1 Vaccine is safe and well tolerated in adults  $\geq 18$  to  $< 65$  years of age. A total of 240 participants were administered a single dose of vaccine containing 15  $\mu\text{g}$  or 30  $\mu\text{g}$  HA. Data for solicited local and systemic and unsolicited adverse events for the 15  $\mu\text{g}$  HA antigen dose are presented as this is the dosage to be administered.

The most common solicited local (injection-site) adverse events observed within 7 days of administration of the vaccine were injection-site tenderness, pain and induration, with the majority of reactions of mild intensity and self-limiting. The most common solicited systemic adverse reactions were headache, myalgia and malaise, with the majority of these events mild to moderate in intensity and similarly self-limiting (Table 3).

In addition, headache was identified as the most common unsolicited adverse event, reported in 11.7 % of participants. Other unsolicited adverse events, reported by more than 2 % of participants, were back pain, arthralgia, seasonal allergy, cough, oropharyngeal pain, nasal congestion, diarrhoea and toothache. There were no reports of serious adverse events.

**Table 3: Proportion of Adult Participants with Solicited Local and Systemic Adverse Events within 7 Days of Administration of Panvax® H1N1 Vaccine, Irrespective of Causality**

Solicited Adverse Event	Proportion of Participants (%) Adults (n = 120) ( ≥ 18 to < 65 years )
<b>Local (injection-site)</b>	
Tenderness	30.8
Pain	20.8
Induration	10.0
Ecchymosis	5.0
Erythema	0.8
<b>Systemic</b>	
Headache	25.8
Myalgia	15.8
Malaise	11.7
Fever	5.8
Nausea	5.8
Chills	0.8
Vomiting	0

**Clinical Trial (Children):**

Preliminary clinical data show that Panvax® H1N1 Vaccine is well tolerated in children, ≥ 6 months to < 9 years of age. In the placebo-controlled trial, 473 participants were administered a single 7.5 µg or 15 µg HA dose of vaccine, or placebo, and were stratified according to age at the date of vaccination: Group A (≥ 6 months to < 3 years) or Group B (≥ 3 years to < 9 years). Data were similar across the antigen doses for each age group. Preliminary results are provided for solicited local and systemic adverse events for the 7.5 µg HA antigen dose for Group A, and for the 15 µg HA antigen dose for Group B, as these are the dosages to be administered.

There were no reports of serious adverse events related to the vaccine. The most common solicited local (injection-site) adverse events observed within 7 days of administration of the vaccine were injection-site pain and erythema, with the majority of reactions of mild intensity and short-lived. The most common solicited systemic adverse reactions for the younger age group (Group A) were irritability, diarrhoea and fever (Table 4). The most common solicited systemic adverse reactions for the older age group, Group B, were headache, fever and malaise (Table 5). The majority of all solicited systemic adverse events were similarly mild in intensity and short-lived.

**Table 4: Proportion of Paediatric Participants with Solicited Local and Systemic Adverse Events within 7 Days of Administration of Panvax® H1N1 Vaccine, Irrespective of Causality (Group A, ≥ 6 months to < 3 years)**

Solicited Adverse Event	Proportion of Participants (%) Group A ≥ 6 mths to < 3 years	
	Placebo n = 24	7.5 µg HA dose n = 103
<b>Local (injection-site)</b>		
Pain	29.2	30.1
Erythema	16.7	27.2
Induration	8.3	17.5
<b>Systemic</b>		
Irritability	8.3	40.8
Diarrhoea	33.3	24.3
Fever	8.3	21.4
Loss of appetite	4.2	12.6
Nausea / Vomiting	4.2	5.8

**Table 5: Proportion of Paediatric Participants with Solicited Local and Systemic Adverse Events within 7 Days of Administration of Panvax® H1N1 Vaccine, Irrespective of Causality (Group B, ≥ 3 years to < 9 years)**

Solicited Adverse Event	Proportion of Participants (%) Group B ≥ 3 to < 9 years	
	Placebo n = 27	15 µg HA dose n = 108
<b>Local (injection-site)</b>		
Pain	18.5	34.3
Erythema	22.2	24.1
Induration	7.4	13.9
<b>Systemic</b>		
Headache	14.8	23.1
Fever	14.8	16.7
Malaise	18.5	16.7
Myalgia	18.5	16.7
Diarrhoea	22.2	7.4
Nausea / Vomiting	7.4	7.4

**Post-marketing surveillance:**

Post-marketing data for Panvax® H1N1 vaccine are limited and have not identified any new safety concerns. It is anticipated that the adverse events after vaccination will be similar to those spontaneously reported during post-approval use of CSL's seasonal influenza vaccine, Fluvax® vaccine. The adverse events reported are presented below according to System Organ Class and frequency. These data reflect experience in children and adults with Fluvax® vaccine.

Adverse event frequencies are defined as follows:

Very common ( $\geq 1/10$ ), common ( $\geq 1/100$  and  $< 1/10$ ), uncommon ( $\geq 1/1000$  and  $< 1/100$ ), rare ( $\geq 1/10\ 000$  and  $< 1/1000$ ) and very rare ( $< 1/10\ 000$ ).

***Blood and Lymphatic System Disorders***

Rare: Transient thrombocytopenia

***Immune System Disorders***

Rare: Allergic reactions including anaphylactic shock

***Nervous System Disorders***

Rare: Neuralgia, paraesthesia and convulsions

Very rare: Encephalitis, neuritis or neuropathy and Guillain-Barré syndrome

***Vascular Disorders***

Very rare: Vasculitis with transient renal involvement

***Skin and Subcutaneous Tissue Disorders***

Uncommon: Pruritus, urticaria and rash

***General Disorders and Administration Site Conditions***

These reactions usually resolve within 1-2 days without treatment.

Very common:	Injection site inflammation Influenza-like illness (for thiomersal-containing vaccine only)
Common:	Injection site ecchymosis and induration Influenza-like illness (for thiomersal-free vaccine only)

Influenza-like illness may include pyrexia, chills, headache, malaise and myalgia.

## **DOSAGE AND ADMINISTRATION**

**Dosage:**

Children 6 months to 35 months:	0.25 mL dose (7.5 µg HA)
Adults and children from 36 months:	0.5 mL dose (15 µg HA)

Children from 6 months to less than 10 years should receive two doses of vaccine, with the second dose given after an interval of at least 4 weeks.

Adults, adolescents and children 10 years of age and older should receive a single dose.

**Administration:**

The vaccine should be administered by intramuscular or deep subcutaneous injection.

It is important that the contents of the container be shaken thoroughly immediately before use. The vaccine should appear as a clear to slightly opaque liquid with some sediment that resuspends upon shaking.

The 0.25 mL and 0.5 mL pre-filled syringes are for single use and any remaining contents should be discarded in accordance with local requirements. The 0.5 mL pre-

filled syringe may also be used to deliver a 0.25 mL dose to children from 6 months to 35 months of age. Before administering the 0.25 mL dose, carefully discard half the volume from the syringe. To do so, depress the plunger to the half dose marking on the syringe barrel. Inject the remaining 0.25 mL of vaccine.

For the multi-dose vials, the conditions for use are:

- the vaccine is stored at 2 - 8°C prior to and immediately after each use
- the vaccine is protected from light during storage
- the vaccine in the vial must be used **within 24 hours** once the stopper has been pierced
- the stopper is to be pierced no more than 18 times to ensure stopper integrity
- aseptic technique must be used to withdraw each dose, using a separate sterile needle and syringe
- following withdrawal of vaccine from the vial, the syringe must be used within the one vaccination session (up to a maximum time interval of 4 hours) and cannot be stored for use at a later date
- at the end of the 24 hour period, any remaining contents within the vials should be discarded in accordance with local requirements.

Ensuring the conditions for vial use are maintained is the responsibility of the healthcare professional administering the vaccine.

## OVERDOSAGE

There is no specific information on overdose of Panvax<sup>®</sup> H1N1 Vaccine.

For general advice on overdose management, contact the Poisons Information Centre on 131 126.

## PRESENTATION AND STORAGE CONDITIONS

### Presentations:

Panvax<sup>®</sup> H1N1 Vaccine is provided in four presentations:

- 0.25 mL single-dose pre-filled syringe (Panvax<sup>®</sup> H1N1 Vaccine Junior)
- 0.5 mL single-dose pre-filled syringe
- 5 mL multi-dose vial
- 10 mL multi-dose vial

For multi-dose vial presentations, thiomersal is added as a preservative; each 0.5 mL dose contains 50 µg of thiomersal. Pre-filled syringe presentations are thiomersal-free. All presentations of Panvax<sup>®</sup> H1N1 Vaccine are latex-free.

### Multi-dose Vial

Each multi-dose vial contains a nominal 5 mL or 10 mL of vaccine and is closed with a latex-free stopper and sealed with an aluminium crimp seal. The aluminium seal has a plastic tear-away cap attached that is removed to gain access to the vial closure. The cap is present to protect the vial closure and to indicate if the vial has been tampered with. Once removed, the cap cannot be re-affixed to the vial. The sealed units are packed into a cardboard carton.

Pack size is 10 or 50 vials.

### **Pre-filled Syringe**

Pre-filled syringes are for single-use only and come with an attached needle for injection. The outside of the 0.5 mL syringe barrel has a graduation mark to allow for a 0.25 mL dose. Each disposable syringe contains a single 0.25 mL or 0.5 mL dose of vaccine and is supplied encased within a clear film wrapper. The presence of the film wrapper provides assurance that the product has not been opened. Do not use if the film wrap is damaged or missing.

Pack size is 1 or 10 syringes.

### **Storage Conditions:**

Panvax<sup>®</sup> H1N1 Vaccine should be stored, protected from light, at 2°C to 8°C. IT MUST NOT BE FROZEN.

The shelf life of the vaccine is 12 months when stored at 2°C to 8°C. The expiry date is indicated on the container label.

## **NAME AND ADDRESS OF THE SPONSOR**

### **Manufactured by:**

CSL Limited ABN 99 051 588 348  
45 Poplar Road, Parkville  
VICTORIA 3052 AUSTRALIA

### **Distributed by:**

CSL Biotherapies Pty Ltd ABN 66 120 398 067  
45 Poplar Road, Parkville  
VICTORIA 3052 AUSTRALIA

## **POISONS SCHEDULE**

Prescription only medicine

## **DATE OF APPROVAL**

Date of TGA approval: 3 December 2009

<sup>®</sup> Registered Trademark of CSL Limited